This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
SpringWorks (SWTX) Surges More Than 80% in 3 Months: Here's Why
by Zacks Equity Research
SpringWorks (SWTX) receives a big boost with the FDA's approval for Ogsiveo (nirogacestat) to treat adult patients with progressing desmoid tumors.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why
by Zacks Equity Research
Travere (TVTX) is on track to file an sNDA to the FDA to convert the accelerated approval for lead drug, Filspari, to full approval for IgAN in first-quarter 2024.
Here's Why Investors May Bet on BioMarin (BMRN) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why investing in BioMarin (BMRN) stock now may turn out to be a more prudent move than ever.
Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study
by Zacks Equity Research
Outlook (OTLK) stock rises after aligning with the FDA regarding the protocols of a non-inferiority study of ONS-5010 for AMD. The study is set to become the basis for BLA resubmission by 2024-end.
Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why
by Zacks Equity Research
Lisata (LSTA) is progressing well with the development of its lead investigational product candidate, LSTA1, which targets several cancer indications.
Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback
by Zacks Equity Research
Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The company's efforts to expand the label of the drug are also encouraging. However, pipeline setback remains a concern.
Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal
by Zacks Equity Research
Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.
J&J's (JNJ) Q4 Earnings Beat, Darzalex, Stelara Drive Sales
by Zacks Equity Research
J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sales of several key drugs like Darzalex, Stelara and Tremfya beat estimates.
Should You Add Marinus (MRNS) Stock to Your Portfolio Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in Marinus Pharmaceuticals' (MRNS) stock may turn out to be a prudent move.
Is Alpha Tau Medical (DRTS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Alpha Tau Medical Ltd. (DRTS) and Regeneron (REGN) have performed compared to their sector so far this year.
S&P 500 Index Hits All-Time High: 5 Must-Buy Stocks
by Nalak Das
We have narrowed our search to five S&P 500 stocks that have strong growth potential in 2024. These are: NVDA, REGN, ANET, IT, MLM.
Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
by Zacks Equity Research
Mesoblast's (MESO) Revascor (rexlemestrocel-L) gets FDA's Rare Pediatric Disease designation for treating children with congenital heart disease. Shares rise in after-hours trading.
Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why
by Zacks Equity Research
Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, targeting two different cancer indications.
Zacks.com featured highlights Otter Tail, OraSure, BioMarin and Regeneron
by Zacks Equity Research
Otter Tail, OraSure, BioMarin and Regeneron have been highlighted in this Screen of The Week article.
MAIA Soars 20% on Interim Results From Lung Cancer Study
by Zacks Equity Research
MAIA Biotechnology (MAIA) reports updated results from a mid-stage study. Patients treated with its lead drug achieved disease control rates that were well-sustained compared with previous scans.
Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why
by Zacks Equity Research
Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.
Novartis' (NVS) Strong Portfolio, Pipeline to Fuel Growth in 2024
by Zacks Equity Research
Novartis (NVS) is poised to outperform in 2024, backed by a diverse portfolio and a deep pipeline.
Is it a Good Idea to Invest in Intellia (NTLA) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in Intellia (NTLA) stock now may turn out to be a more prudent move than ever.
Here's Why You Should Invest in Avadel (AVDL) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why buying Avadel Pharmaceuticals (AVDL) stock now may turn out to be a prudent move.
Buy These 4 Low-Beta Stocks to Counter Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Otter Tail (OTTR), Regeneron (REGN), OraSure (OSUR) and BioMarin Pharmaceutical (BMRN) are well-poised to gain.
Exelixis (EXEL) Outperforms on Cabometyx and Pipeline Progress
by Zacks Equity Research
Exelixis' (EXEL) lead drug, Cabometyx, maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.
Regeneron (REGN), Sanofi's Dupixent Gets Label Update in US
by Zacks Equity Research
The FDA updates Regeneron (REGN) and Sanofi's Dupixent label in the United States to include efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement.
Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO
by Zacks Equity Research
Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.
Regeneron and Petco Health and Wellness have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Regeneron and Petco Health and Wellness have been highlighted as Zacks Bull and Bear of the Day.